MITSUBISHI TANABE PHARMA CORPORATION

English German


LEARN ABOUT HIT
What is HIT?
What causes HIT?
What are the complications?
When does HIT occur?
THE HIT PATIENT
Who is the patient?
When to suspect HIT
Estimating the probability
4Ts
After cardiac surgery
Laboratory testing for HIT
Managing the HIT patient
The ICU patient
Treatment options
Ask the Expert
RESOURCES
Whats New
Bulletins
Further Information
ABOUT ARGATROBAN
Introduction
Argatroban
Key features
Differentiation
Patient benefits
How does it work?
Clinical efficacy
Safety profile
Dosage guidelines
Dosage calculator
Preparation
References
SPC
Austria
Denmark
Germany
Iceland
Italy
The Netherlands
Norway
Sweden
PIL
Austria
Denmark
Germany
Iceland
Italy
The Netherlands
Norway
Sweden
Ordering
FAQs
Use in dialysis
CONTACT
Europe
Austria
Germany
Sweden
Denmark
Norway
Iceland
Italy
The Netherlands
External sites

Click for SPC

Healthcare

Site map / Terms of Use

Home / Site Map and Terms / Site Map

Home


LEARN ABOUT HIT

What is HIT?

What causes HIT?

What are the complications?

When does HIT occur?


THE HIT PATIENT

Who is the patient?

When to Suspect HIT

Estimating the Probability

4ts

After Cardiac Surgey

Laboratory testing for HIT

Managing the HIT patient

The ICU patient

Treatment Options

Ask the Expert


RESOURCES

What's New

Bulletin's

Further Information


ABOUT ARGATROBAN

Introduction

Argatroban 

Key Features

Differentiation

Patient Benefits

How Does It Work

Clinical Efficacy

Safety Profile

Dosage Guidelines

Dosage Calculator

Preparation 

References

SPC

Austria

Denmark

Germany

Iceland

Italy

The Netherlands

Norway

Sweden   

PIL

Austria

Denmark

Germany

Iceland

Italy

The Netherlands

Norway

Sweden 

Ordering


FAQS

Use in dialysis


CONTACT

Europe

Austria

Germany

Sweden

Denmark

Norway

Iceland

The Netherlands

External Links


TERMS OF USE

 

© Mitsubishi Pharma Europe Ltd 2008